Indian and other foreign semaglutide products can attract attention because of brand variety and differences in local market rules. But U.S. pharmaceutical approval is product-specific: approval in India does not authorize selling that finished medicine as FDA-approved Ozempic, Wegovy or a generic substitute to U.S. buyers. An advertisement may describe the same active ingredient without establishing the same regulator-reviewed formulation.
FDA’s September 23, 2026 warning letter to an online seller specifically identified the advertised “Semanat Injection (Semaglutide)” as lacking an effective FDA-approved drug application. This is evidence about that U.S.-facing offer, not a conclusion that every medicine made in India or every Indian pharmaceutical manufacturer is unlawful. Foreign facilities can participate in legitimate U.S. supply chains when the relevant products meet U.S. requirements.
This guide covers the U.S. import and approval question, not shopping links or overseas prices. To identify Indian products as market entities, visit the Indian semaglutide brand directory. For products currently approved for U.S. use, consult the FDA-approved semaglutide directory.
To verify a marketed drug, identify its actual brand, ingredient, route, strength, manufacturer or application holder and approval status in U.S. FDA records. A foreign national registration, patent expiration or clinical trial does not itself constitute an approved U.S. new-drug or generic application.
The generic semaglutide guide explains how to distinguish an FDA-approved generic from a drug using the same molecule under another country’s legal system.
Similar-sounding claims may refer to different things: the finished medicine, an active ingredient for manufacture, the identity of a foreign brand or the legal status of a U.S. seller. Keep these categories separate when evaluating a promotion.
This comparison is a regulatory decision tool, not a recommendation to order a product from overseas.
| Claim encountered | What it actually establishes | What to check for U.S. use |
|---|---|---|
| “Approved in India” | Domestic authorization in India, subject to exact product | FDA drug approval for the U.S. presentation |
| “Contains semaglutide” | Ingredient identity asserted by advertiser | Approved finished product, formulation and supply chain |
| “Made in India for U.S. market” | Foreign manufacturing location alone is not decisive | Approved application, compliant facility and authorized distribution |
| “FDA-approved generic Ozempic from India” | Marketing claim requiring proof | Specific effective ANDA in Drugs@FDA/Orange Book |
| “Personal import is always allowed” | Overbroad legal claim | FDA import restrictions and case-specific rules |
| “Compounded using imported API” | Different legal route than importing finished brand | 503A/503B and relevant API import requirements |
In a warning letter dated September 23, 2026, FDA described an online seller’s promotion of “Semanat Injection (Semaglutide)” and stated there was no effective approved drug application covering the product offered on that website. The agency characterized the offer as involving unapproved drug marketing under U.S. law.
This finding is narrower than an assertion that a brand cannot have authorization anywhere else. It also is not a complete registry of all Indian semaglutide brands; a product-by-product review remains necessary.
India’s semaglutide market changed in 2026 as local companies introduced or licensed products. Brands may differ in intended local indication, injection device, commercial marketer, formulation or regulator registration. The brand catalog documents those distinctions without functioning as a U.S. shopping directory.
A U.S. consumer should not assume legal delivery, FDA approval, clinical interchangeability or insurance reimbursement merely from the Indian market launch of a product.
Medicines manufactured outside the United States are not automatically forbidden. FDA oversight of products and production, approval status and import requirements can permit legally authorized drugs from compliant international facilities. That process differs substantially from a website shipping a locally approved overseas brand straight to a U.S. consumer.
Distinguish the location of manufacture from the regulatory approval of the finished U.S. presentation and the status of the dispensing channel.
FDA import law can restrict unapproved prescription-drug entry, even if the buyer has a prescription and intends to use the product personally. Limited FDA enforcement discretion policies should not be mistaken for a general right to import a foreign semaglutide brand.
Do not rely on forum claims that customs will always release packages, that a small quantity is automatically legal, or that any foreign prescription overrides U.S. product approval requirements.
A foreign generic is authorized under another market’s legal framework. An FDA-approved U.S. generic requires its own approved application, and a compounded medicine is prepared under separate pharmacy or outsourcing requirements without FDA approval of the compounded product.
These are three different categories. For the compounding-specific rules, see the FDA compounding guide; for an FDA generic status check, see generic verification.
Even where a product is correctly identified as foreign, a separate question is whether the seller is a licensed U.S. dispensing pharmacy and whether a lawful prescription and distribution route exist. Concealed origin, “worldwide no-Rx delivery” claims and indistinct manufacturer identities are warning signs.
Use the step-by-step U.S. pharmacy verification process before providing prescription details or payment information.
Injection delivery devices, excipients, strength expressions and product instructions can differ even when two products both claim semaglutide. An unreviewed foreign presentation does not inherit the U.S. label or risk-benefit assessment of Ozempic or Wegovy.
Patient decisions about approved products belong with the licensed prescriber; an online retailer cannot validate a personal substitution simply by matching an ingredient name.
Keep the container, carton, invoice and shipping information, and speak with a licensed pharmacist or clinician before use. The regulatory question of authorization and the physical question of authenticity must both be addressed. Report suspicious marketing or adverse events through the relevant FDA processes as appropriate.
For suspected falsification or tampering, use the counterfeit product response guide. Do not attempt independent dosing conversions or product testing.
The legitimate U.S. pathways for indicated semaglutide treatment begin with the relevant FDA-approved product, licensed clinical decision and state-licensed pharmacy. More specific next steps appear in the Ozempic acquisition guide and the Wegovy acquisition guide.
This page does not provide affiliates, shipping links, prices or ordering directions for unapproved imported brands.
This independent guide explains product and purchasing questions but is not a pharmacy, prescriber, insurer, product-authentication laboratory or real-time inventory service. Some outbound commercial links elsewhere on this website may be affiliate or sponsored referrals, and the site may receive compensation when readers use them. Such relationships are disclosed alongside the relevant outbound link; compensation does not validate a seller or guarantee a prescription. Regulatory information was checked against FDA and other named official guidance on October 18, 2026; verify current requirements before acting.
The September 23, 2026 FDA warning letter and current FDA import and drug approval guidance were reviewed on October 18, 2026. This article is a factual explanation of U.S. regulatory categories rather than personalized legal advice or authorization to import a particular product.
Not automatically. Indian authorization and U.S. FDA approval are separate product-specific regulatory decisions.
The name or ingredient is not sufficient. A product intended for U.S. sale must meet applicable FDA approval, labeling and distribution requirements.
FDA identified a U.S.-facing seller offering Semanat Injection without an effective approved drug application for that product.
No. Foreign manufacturing can be part of an authorized U.S. drug supply chain if the specific product and facilities meet U.S. requirements.
No. A prescription does not alone resolve FDA approval and import requirements.
No. FDA enforcement-discretion situations are limited and do not establish blanket permission for importing unapproved semaglutide.
No. Compounding, a foreign nationally approved generic and an FDA-approved U.S. generic follow different legal routes.
Ingredient and number similarity do not establish device, formulation or clinical interchangeability. Consult a licensed clinician and pharmacist.
Keep the packaging and transaction details and seek qualified pharmacy or medical advice before use. Do not self-convert doses or assume authenticity.